Studies on both in vitro and in vivo OS models indicate that anti-CD47 monoclonal antibodies can hinder the CD47-SIRPα signaling pathway, thereby bolstering the anti-tumor capabilities of macrophages (115). The gene discussed is CD47; the disease is neoplasm.